Abstract

Parkinson disease (PD) is the second most common age-related neurodegenerative condition diagnosed in North America. We recently demonstrated, using multiple epidemiological data sources, that the prevalence of PD diagnoses was greater than previously reported and currently used for clinical, research, and policy decision-making. Prior PD incidence estimates have varied, for unclear reasons. There is a need for improved estimates of PD incidence, not only for care delivery planning and future policy but also for increasing our understanding of disease risk. The objective of this study was thus to investigate the incidence of Parkinson disease across five epidemiological cohorts in North America in a common year, 2012. The cohorts contained data on 6.7 million person-years of adults ages 45 and older, and 9.3 million person-years of adults ages 65 and older. Our estimates of age-sex-adjusted incidence of PD ranged from 108 to 212 per 100,000 among persons ages 65 and older, and from 47 to 77 per 100,00 among persons ages 45 and older. PD incidence increased with age and was higher among males. We also found persistent spatial clustering of incident PD diagnoses in the U.S. PD incidence estimates varied across our data sources, in part due to case ascertainment and diagnosis methods, but also possibly due to the influence of population factors (prevalence of genetic risk factors or protective markers) and geographic location (exposure to environmental toxins). Understanding the source of these variations will be important for health care policy, research, and care planning.

Details

Title
Incidence of Parkinson disease in North America
Author
Willis, A. W. 1   VIAFID ORCID Logo  ; Roberts, E. 2 ; Beck, J. C. 3   VIAFID ORCID Logo  ; Fiske, B. 4   VIAFID ORCID Logo  ; Ross, W. 5 ; Savica, R. 6 ; Van Den Eeden, S. K. 7   VIAFID ORCID Logo  ; Tanner, C. M. 8   VIAFID ORCID Logo  ; Marras, C. 9 ; Alcalay, Roy; Schwarzschild, Michael; Racette, Brad; Chen, Honglei; Church, Tim; Wilson, Bill; Doria, James M.

 University of Pennsylvania, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 Verge Genomics, San Francisco, USA (GRID:grid.25879.31) 
 Parkinson’s Foundation, Miami, USA (GRID:grid.453428.c) (ISNI:0000 0001 2236 2879) 
 Michael J. Fox Foundation, New York, USA (GRID:grid.430781.9) (ISNI:0000 0004 5907 0388) 
 Pacific Health Research and Education Institute, Honolulu, USA (GRID:grid.417341.4) (ISNI:0000 0004 0625 7560) 
 Mayo Clinic, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Kaiser Permanente Northern California, Oakland, USA (GRID:grid.280062.e) (ISNI:0000 0000 9957 7758) 
 University of California at San Francisco, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of Toronto, Toronto, USA (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
Pages
170
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
23738057
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2754660050
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.